SABCS 2016: Extended Letrozole Therapy May Have Limited Benefits

Data presented at the San Antonio Breast Cancer Symposium showed that five additional years of the aromatase inhibitor (AI) therapy letrozole (Femara) following an initial five years of AI-based adjuvant hormone therapy did not significantly improve survival outcomes in postmenopausal women with early-stage HR-positive breast cancer. The additional five years did improve some outcomes related to recurrence.

Read More

SABCS 2016: Co-director Carlos L. Arteaga, MD, Previews Breast Cancer Symposium

SABCS is a comprehensive scientific meeting that provides the latest information on prevention, diagnosis, and treatment of breast cancer and premalignant breast disease to various stakeholders in the field.

Read More

Increasing Awareness of Breast Cancer Health Disparities

This month is Breast Cancer Awareness Month, a type of cancer against which we have made much progress. However, a recent report from the Centers for Disease Control and Prevention (CDC) highlights that the progress we are making has not been uniform for all segments of the population.

Read More

SABCS 2014: Immunotherapy Shows Early Promise for Triple-negative Breast Cancer Patients

After making great strides for some patients with melanoma and lung cancer, immunotherapy drugs are starting to offer hope for women with a very challenging form of breast cancer—triple-negative breast …

Read More